...
机译:Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis
Hepatology DepartmentPeking University People’s HospitalBeijing,China;
Zhengzhou Municipal Sixth People's HospitalZhengzhou,China;
Nanjing Municipal Second HospitalNanjing,ChinaBeijing Key Laboratory for Hepatitis C and Immunotherapy for Liver DiseasePeking University PeopleShenyang Municipal Sixth People's HospitalShenyang,ChinaGuangzhou Municipal Eighth People's HospitalGuanzhou,ChinaChinese PLA Third Military Medical University First Affiliated HospitalChongqing,ChinaQingdao Municipal HospitalQingdao,ChinaJi'nan Municipal Hospital of Infectious DiseaseJi'nan,Shandong,ChinaDalian Municipal Sixth People's HospitalDalian,ChinaCapital Medical University Affiliated Beijing Friendship HospitalBeijing,ChinaJilin University First HospitalChangchun,ChinaYanbian University Affiliated HospitalYanji,ChinaBeijing Kawin Technology Share‐holding Co., Ltd.Beijing,ChinaHepatopancreatobiliary CenterBeijing Tsinghua Changgung HospitalBeijing,China;
coblopasvir; direct‐acting antiviral; hepatitis C virus; pangenotypic; sofosbuvir;